Company Overview
About Mindstate Design Labs
Mindstate Design Labs is a Los Angeles-based clinical-stage biotech developing non-hallucinogenic psychedelic therapeutics — using computational neuroscience and machine learning to engineer psychedelic-inspired molecules that activate the neural mechanisms associated with therapeutic benefit (neuroplasticity, serotonin receptor modulation) while minimizing or eliminating the dissociative hallucinogenic effects that limit psychedelic therapy to clinical settings. A Y Combinator W21 graduate, Mindstate raised $25.5 million total, achieved $1.3 million in revenue in 2024 with a 19-person team, and received FDA and EMA approval for Phase I human trials of lead program MSD-001 in 2024, backed by founders of OpenAI, Neuralink, Coinbase, and Initialized Capital.
Business Model & Competitive Advantage
Mindstate's AI platform models the binding profiles and downstream signaling of psychedelic compounds across multiple serotonin receptor subtypes (5-HT2A, 5-HT2C, etc.) to predict which modifications produce therapeutic neuroplasticity effects with minimal perceptual distortion. This computational drug design approach — screening thousands of molecular variants in silico before synthesis — enables faster iteration toward the therapeutic-without-hallucinogenic profile that would make psychedelic-inspired drugs prescribable in standard clinical settings rather than requiring 8-hour supervised sessions.
Competitive Landscape 2025–2026
In 2025, Mindstate Design Labs competes in the psychedelic medicine and CNS drug discovery space with COMPASS Pathways (psilocybin for TRD, NASDAQ: CMPS), MindMed (LSD/psychedelic therapeutics, NASDAQ: MNMD), Lykos Therapeutics (MDMA-assisted therapy, FDA-rejected in 2024), and the broader non-hallucinogenic psychedelic programs at Delix Therapeutics and Entheogen Biosciences for psychiatric disorder therapeutics. The 2024 FDA rejection of MDMA-assisted therapy for PTSD created a setback for the psychedelic medicine field, highlighting the regulatory challenge of approving compounds with significant subjective effects. Mindstate's non-hallucinogenic approach directly addresses this regulatory barrier. The prestigious backer names (OpenAI/Neuralink founders, Initialized Capital) validate the AI drug design thesis. The Phase I FDA approval is the critical 2025 milestone. The 2025 strategy focuses on completing Phase I safety data for MSD-001, expanding the molecular candidate pipeline, and building the regulatory relationships that will be critical for Phase II/III pathway.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Mindstate Design Labs is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Compare Mindstate Design Labs with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Mindstate Design Labs? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Mindstate Design Labs Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Mindstate Design Labs vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →